Calendula Calendula officinalis L.
Also called: calendula flower, Calendulae flos (EU herbal substance name)
Calendula is a flowering plant of the daisy family (Asteraceae) native to the western Mediterranean. EU and Health Canada monographs cover preparations of the dried flower applied to the skin or used in the mouth; Health Canada also has an oral monograph.
- Category
- Botanical
- Part used
- Flower (infusions, tinctures, liquid extracts, oil extracts, ointments and creams)
- Strongest evidence
- C Limited
- Native range
- Native to the western Mediterranean (POWO: "W. Medit."; native distribution listed as Spain)
- Reviewed
- 2026-10-30
Class 1 Well studied in people. This entry cites 11 RCTs of calendula alone, all topical or vaginal (ten topical, one vaginal cream); no oral-use RCT is counted. No source stating a total count was found. [6]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CPregnancy and infants2 topics
CSkin and hair1 topic
CHormones and reproduction1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Acute radiation dermatitis during radiotherapy (topical, pooled trials) | C | A 2023 meta-analysis of RCTs of natural agents applied during radiotherapy found calendula did not significantly lower the incidence of grade 2+ radiation dermatitis; the authors called the evidence for natural agents inconsistent. [5] |
| Radiation dermatitis in breast cancer radiotherapy versus trolamine (topical) | C | A phase III RCT in 254 breast cancer patients found grade 2 or higher acute dermatitis was less frequent with calendula ointment than trolamine (41% vs 63%), with less radiation-induced pain. [6] |
| Wound healing (topical) | C | A 2019 systematic review of calendula extract alone (7 clinical trials, 7 animal studies) found some evidence for acute wounds and mixed results for venous and diabetic ulcers and burns; larger trials are needed. [4] |
| Diaper dermatitis in infants (topical) | C | In a 100-infant RCT, bentonite cream worked faster and more completely than calendula cream (86% vs 52% of infants with lesions completely improved within three days). [8] |
| Pain after episiotomy (topical ointment) | C | A single-center RCT in 100 women found lower pain scores from day two onward with calendula ointment than standard care, with less redness and edema. [9] |
| Vaginal candidiasis (vaginal cream versus clotrimazole) | C | In a triple-blind RCT (150 women), fewer tested negative with calendula than clotrimazole at 10–15 days (49% vs 74%), but more did at 30–35 days (77% vs 34%). [10] |
Main constituents: Triterpenoids (named by MSK in connection with anti-inflammatory and antiviral activity); lutein and beta-carotene are found in leaves and stems [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Ointment applied 4 hours after episiotomy and then every 8 hours for 10 days (episiotomy trial). [9]
- 5 g of vaginal cream every night for seven nights (vaginal candidiasis trial). [10]
- EU traditional-use monograph (2018), cutaneous: infusion of 1–2 g in 150 ml water for dressings left on 30–60 minutes, or semi-solid preparations with 2–20% herbal substance, up to 2–4 times daily. [1]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingEU monograph: safety during pregnancy and lactation has not been established, so use is not recommended; no fertility data are available.
4 statements in the profile.
Details and sources - Interactions with medicines1 listed
Medicines in general
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications1 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographs4 statements
EU HMPC traditional-use monograph (adopted 27 March 2018), cutaneous use (adults, adolescents, children and elderly): infusion of 1–2 g in 150 ml …
Details and sources
- EU monograph: contraindicated in people hypersensitive to calendula or other plants of the Asteraceae (Compositae) family; skin sensitization has been reported (frequency unknown). [1]
- EU monograph: use in pregnancy and lactation is not recommended because safety has not been established; skin use is not recommended under 6 years and mouth or throat use under 12 years. [1]
- MSK: calendula is known to cause allergic reactions; avoid during pregnancy and breastfeeding and if allergic to plants in the daisy family. [2]
- Health Canada's oral calendula monograph states "Do not use if you are pregnant" and asks breastfeeding users to consult a health care professional first. [3]
Interactions
| With | What happens |
|---|---|
| Medicines in general | The EU herbal monograph states that no interactions have been reported. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- The EU monograph covers specific preparations: comminuted flower, liquid extracts (1:1; 1:1.8–2.2 in 40–50% ethanol), a 1:5 tincture (70–90% ethanol), a 1:10 extract in fatty vegetable oil, and 1:5–1:25 extracts in hardened fat or petroleum jelly. [1]
Regulatory status
- EU: HMPC traditional-use monograph (Revision 1, adopted 27 March 2018) for symptomatic treatment of minor skin inflammations (such as sunburn), as an aid in healing minor wounds, and for minor mouth or throat inflammations. [1]
- Canada: Health Canada NNHPD has topical and oral calendula monographs (January 30, 2026); the topical uses are traditional herbal-medicine uses for minor wounds and for relief of skin inflammations and irritations. [7]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 1 entry naming calendula (NDI 908 submitted 2016-01-19), a combination listing calendula oil with vitamins A and E and lavender, rosemary and chamomile oils; NDI 128 names Wedelia calendula, a different plant. Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P5]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of calendula (Calendula officinalis) was found (IARC Monographs list of classifications, Volumes 1–142, and NTP technical reports checked 2026-10-29). [P6]
- The NTP Technical Reports index (TR-001 to TR-606) lists no study of calendula (checked 2026-10-29). [P7]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Medicines in general: The EU herbal monograph (2018) states that no interactions have been reported. [P2]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; a firm may petition FDA for an exemption under 111.75(a)(1)(ii). [P8]
Supply and conservation
- GBIF species API returns IUCN category Not Evaluated (NE) for Calendula officinalis L., retrieved 2026-10-29. [P9]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- EU HMPC traditional-use monograph (adopted 27 March 2018), cutaneous use (adults, adolescents, children and elderly): infusion of 1–2 g in 150 ml water for impregnated dressings left on 30–60 minutes, or semi-solid preparations containing 2–20% herbal substance applied thinly, up to 2–4 times daily; see a doctor if symptoms persist beyond 1 week. [P2]
- EU HMPC monograph, oromucosal use (adolescents, adults and elderly): rinse or gargle with a warm infusion of 1–2 g in 150 ml water, or the 1:5 tincture as a gargle or mouthwash in a 2% solution, up to 2–4 times daily. [P2]
- Health Canada NNHPD oral calendula monograph (January 30, 2026), adults 18 and older: 0.18–12 grams dried flower per day. [P3]
- Health Canada NNHPD topical calendula monograph (January 30, 2026): semi-solid forms with 2–20% dried flower or 5–10% tincture or fluid extract; liquid forms with 90–100% (decoction, infusion) or 1–100% (tincture, fluid extract) of extract in the finished product. [P4]
Pregnancy and breastfeeding
- EU monograph: safety during pregnancy and lactation has not been established, so use is not recommended; no fertility data are available. [P2]
- Health Canada oral monograph: "Do not use if you are pregnant"; consult a health care professional before use if breastfeeding. [P3]
- Health Canada topical monograph: consult a health care professional before use if you are pregnant. [P4]
- MSK: avoid during pregnancy and breastfeeding; safety data are lacking. [P1]
Sources for this profile
- Memorial Sloan Kettering Cancer Center. About Herbs: Calendula (Last Updated June 19, 2023), 2023-06-19. mskcc.org
- European Medicines Agency, HMPC. European Union herbal monograph on Calendula officinalis L., flos, Revision 1 (EMA/HMPC/437450/2017; adopted 27 March 2018), 2018-03-27. ema.europa.eu
- Health Canada, NNHPD. Monograph: Calendula - Oral (dated January 30, 2026), 2026-01-30. webprod.hc-sc.gc.ca
- Health Canada, NNHPD. Monograph: Calendula - Topical (dated January 30, 2026), 2026-01-30. webprod.hc-sc.gc.ca
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications, Volumes 1–142 (retrieved 2026-10-29), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; retrieved 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- GBIF species API: IUCN Red List category for Calendula officinalis L., 2026-10-29. api.gbif.org
Sources
- European Medicines Agency, HMPC. European Union herbal monograph on Calendula officinalis L., flos, Revision 1 (EMA/HMPC/437450/2017; adopted 27 March 2018), 2018-03-27. ema.europa.eu
- Memorial Sloan Kettering Cancer Center. About Herbs: Calendula (Last Updated June 19, 2023), 2023-06-19. mskcc.org
- Health Canada, NNHPD. Monograph: Calendula - Oral (dated January 30, 2026), 2026-01-30. webprod.hc-sc.gc.ca
- Givol O, et al. A systematic review of Calendula officinalis extract for wound healing. Wound Repair Regen 2019;27(5):548-561 (PMID 31145533), 2019-09. pubmed.ncbi.nlm.nih.gov
- Robijns J, et al. Natural and miscellaneous agents for the prevention of acute radiation dermatitis: a systematic review and meta-analysis. Support Care Cancer 2023;31(3):195 (PMID 36859690), 2023-03. pubmed.ncbi.nlm.nih.gov
- Pommier P, et al. Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. J Clin Oncol 2004;22(8):1447-1453 (PMID 15084618), 2004-04. pubmed.ncbi.nlm.nih.gov
- Health Canada, NNHPD. Monograph: Calendula - Topical (dated January 30, 2026), 2026-01-30. webprod.hc-sc.gc.ca
- Mahmoudi M, Adib-Hajbaghery M, Mashaiekhi M. Comparing the effects of bentonite and calendula on the improvement of infantile diaper dermatitis: a randomized controlled trial. Indian J Med Res 2015;142(6):742-746 (PMID 26831423), 2015-12. pubmed.ncbi.nlm.nih.gov
- De Angelis C, et al. Use of calendula ointment after episiotomy: a randomized clinical trial. J Matern Fetal Neonatal Med 2022;35(10):1860-1864 (PMID 32460565), 2022-05. pubmed.ncbi.nlm.nih.gov
- Saffari E, et al. Comparing the effects of Calendula officinalis and clotrimazole on vaginal candidiasis: a randomized controlled trial. Women Health 2017;57(10):1145-1160 (PMID 27880086), 2017-11. pubmed.ncbi.nlm.nih.gov
- Sharp L, et al. No differences between Calendula cream and aqueous cream in the prevention of acute radiation skin reactions: results from a randomised blinded trial. Eur J Oncol Nurs 2013;17(4):429-435 (PMID 23245940), 2013-08. pubmed.ncbi.nlm.nih.gov
- Siddiquee S, et al. Efficacy of topical Calendula officinalis on prevalence of radiation-induced dermatitis: a randomised controlled trial. Australas J Dermatol 2021;62(1):e35-e40 (PMID 32965030), 2021-02. pubmed.ncbi.nlm.nih.gov
- Schneider F, Danski MT, Vayego SA. Usage of Calendula officinalis in the prevention and treatment of radiodermatitis: a randomized double-blind controlled clinical trial. Rev Esc Enferm USP 2015;49(2):221-228 (PMID 25992820; article in Portuguese), 2015-04. pubmed.ncbi.nlm.nih.gov
- Giostri GS, et al. Treatment of acute wounds in hand with Calendula officinalis L.: a randomized trial. Tissue Barriers 2022;10(3):1994822 (PMID 34674610), 2022-07. pubmed.ncbi.nlm.nih.gov
- Panahi Y, et al. A randomized comparative trial on the therapeutic efficacy of topical aloe vera and Calendula officinalis on diaper dermatitis in children. ScientificWorldJournal 2012;2012:810234 (PMID 22606064), 2012-04. pubmed.ncbi.nlm.nih.gov
- Sharifi-Heris Z, et al. Comparison the effects of topical application of olive and calendula ointments on children's diaper dermatitis: a triple-blind randomized clinical trial. Dermatol Ther 2018;31(6):e12731 (PMID 30311724), 2018-11. pubmed.ncbi.nlm.nih.gov
- Crnčević MŠ, et al. Double-blind randomised controlled trial of an emollient cream with and without 1% supercritical CO2 extract of Calendula officinalis in contact dermatitis. Acta Pharm 2025;75(4):699-708 (PMID 41527980), 2025-12. pubmed.ncbi.nlm.nih.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Calendula officinalis L. (accessed 2026-10-29; native range: "W. Medit."), 2026-10-29. powo.science.kew.org
- European Medicines Agency. Calendulae flos (herbal medicine overview page; Revision 1 monograph first published 14/06/2018), 2018-06-14. ema.europa.eu
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.